First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a [...]
HERTFORDSHIRE, England, and PITTSBURGH– August 19, 2020 – Mylan N.V. (NASDAQ: MYL) today announced the launch of the first [...]
"The Trump administration's official withdrawal from the World Health Organization (WHO) puts the health of our country at grave risk. As [...]
The US FDA has approved inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 [...]
Sue Bennett with June Halper POSTPONEMENT Due to continued concerns regarding COVID, only a limited amount of people are able to [...]
In light of the COVID-19 pandemic and its impact on the MS community, please know the Multiple Sclerosis Association of American (MSAA) has [...]
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of [...]
